Immunomodulation of mesenchymal stromal cells on regulatory T cells and its possible mechanism

Experimental Cell Research

Volumn 324, Issue 1, 2014, Pages 65-74

  Yan, Zhidong ^a   Zhuansun, Yongxun ^a   Chen, Rui ^a   Li, Jianguo ^a   Ran, Pixin ^b  

^a SUN YAT SEN UNIVERSITY   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Immunomodulation; Mesenchymal stromal cells; Programmed cell death 1 receptor; Regulatory T cells

Indexed keywords

INTERLEUKIN 10; PROGRAMMED DEATH 1 RECEPTOR; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CELL PROLIFERATION ASSAY; CELL VIABILITY; COCULTURE; CYTOKINE RELEASE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOMODULATION; IN VITRO STUDY; MESENCHYMAL STROMA CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; UPREGULATION;

IMMUNOMODULATION; MESENCHYMAL STROMAL CELLS; PROGRAMMED CELL DEATH 1 RECEPTOR; REGULATORY T CELLS;

ADOLESCENT; ADULT; CELLS, CULTURED; COCULTURE TECHNIQUES; CYTOKINES; GENE EXPRESSION REGULATION; HUMANS; IMMUNOMODULATION; LYMPHOCYTE ACTIVATION; MESENCHYMAL STROMAL CELLS; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY; YOUNG ADULT;

EID: 84899474275     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2014.03.013     Document Type: Article

References (58)

1. Uccelli A., Moretta L., Pistoia V. Mesenchymal stem cells in health and disease. Nat. Rev. Immunol. 2008, 8(9):726-736.
2. Karlsson H., Samarasinghe S., Ball L.M., et al. Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T-cell responses. Blood 2008, 112(3):532-541.
3. Karlsson H., Erkers T., Nava S., et al. Stromal cells from term fetal membrane are highly suppressive in allogeneic settings in vitro. Clin. Exp. Immunol. 2012, 167(3):543-555.
4. Han K.H., Kang H.G., Gil H.J., et al. The immunosuppressive effect of embryonic stem cells and mesenchymal stem cells on both primary and secondary alloimmune responses. Transpl. Immunol. 2010, 23(3):141-146.
5. Han K.H., Ro H., Hong J.H., et al. Immunosuppressive mechanisms of embryonic stem cells and mesenchymal stem cells in alloimmune response. Transpl. Immunol. 2011, 25(1):7-15.
6. Liu D., Xu J., Liu O., et al. Mesenchymal stem cells derived from inflamed periodontal ligaments exhibit impaired immunomodulation. J. Clin Periodontol. 2012, 39(12):1174-1182.
7. Calkoen F.G., Brinkman D.M., Vervat C., et al. Mesenchymal stromal cells isolated from children with systemic juvenile idiopathic arthritis suppress innate and adaptive immune responses. Cytotherapy 2013, 15(3):280-291.
8. Ball L.M., Bernardo M.E., Roelofs H., et al. Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. Blood 2007, 110(7):2764-2767.
9. Ball L.M., Bernardo M.E., Roelofs H., et al. Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus-host disease. Br. J. Haematol. 2013, 163(4):501-509.
10. Ding G., Wang W., Liu Y., et al. Mesenchymal stem cell transplantation: a potential therapy for oral lichen planus. Med. Hypotheses 2011, 76(3):322-324.
11. Xu J., Zheng Z., Fang D., et al. Mesenchymal stromal cell-based treatment of jaw osteoradionecrosis in Swine. Cell Transpl. 2012, 21(8):1679-1686.
12. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000, 101(5):455-458.
13. + suppressor T cells: more questions than answers. Nat. Rev. Immunol. 2002, 2(6):389-400.
14. + regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 2004, 22:531-562.
15. Fontenot J.D., Rasmussen J.P., Gavin M.A., et al. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat. Immunol. 2005, 6(11):1142-1151.
16. von Boehmer H. Mechanisms of suppression by suppressor T cells. Nat. Immunol. 2005, 6(4):338-344.
17. Vignali D.A., Collison L.W., Workman C.J. How regulatory T cells work. Nat. Rev. Immunol. 2008, 8(7):523-532.
18. Raimondi G., Shufesky W.J., Tokita D., et al. Regulated compartmentalization of programmed cell death-1 discriminates CD4+CD25+ resting regulatory T cells from activated T cells. J. Immunol. 2006, 176(5):2808-2816.
19. Nishimura H., Nose M., Hiai H., et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999, 11(2):141-151.
20. Okazaki T., Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int. Immunol. 2007, 19(7):813-824.
21. Liang S.C., Latchman Y.E., Buhlmann J.E., et al. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur. J. Immunol. 2003, 33(10):2706-2716.
22. Totsuka T., Kanai T., Makita S., et al. Regulation of murine chronic colitis by CD4+CD25- programmed death-1+ T cells. Eur. J. Immunol. 2005, 35(6):1773-1785.
23. Barber D.L., Wherry E.J., Masopust D., et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006, 439(7077):682-687.
24. Burr S.P., Dazzi F., Garden O.A. Mesenchymal stromal cells and regulatory T cells: the Yin and Yang of peripheral tolerance. Immunol. Cell. Biol. 2013, 91(1):12-18.
25. Keir M.E., Butte M.J., Freeman G.J., et al. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 2008, 26:677-704.
26. Augello A., Tasso R., Negrini S.M., et al. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur. J. Immunol. 2005, 35(5):1482-1490.
27. Sheng H., Wang Y., Jin Y., et al. A critical role of IFNgamma in priming MSC-mediated suppression of T cell proliferation through up-regulation of B7-H1. Cell Res. 2008, 18(8):846-857.
28. Djouad F., Plence P., Bony C., et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003, 102(10):3837-3844.
29. Krampera M., Glennie S., Dyson J., et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003, 101(9):3722-3729.
30. Crop M.J., Baan C.C., Korevaar S.S., et al. Human adipose tissue-derived mesenchymal stem cells induce explosive T-cell proliferation. Stem Cells Dev. 2010, 19(12):1843-1853.
31. Le Blanc K., Frassoni F., Ball L., et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008, 371(9624):1579-1586.
32. Tan J., Wu W., Xu X., et al. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial. JAMA 2012, 307(11):1169-1177.
33. Connick P., Kolappan M., Crawley C., et al. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol. 2012, 11(2):150-156.
34. Hare J.M., Fishman J.E., Gerstenblith G., et al. Comparison of allogeneic vs. autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA 2012, 308(22):2369-2379.
35. + regulatory T cells. J. Exp. Med. 2005, 201(7):1061-1067.
36. Sun J., Madan R., Karp C.L., et al. Effector T cells control lung inflammation during acute influenza virus infection by producing IL-10. Nat. Med. 2009, 15(3):277-284.
37. Nemeth K., Keane-Myers A., Brown J.M., et al. Bone marrow stromal cells use TGF-beta to suppress allergic responses in a mouse model of ragweed-induced asthma. Proc. Natl. Acad. Sci. U S A 2010, 107(12):5652-5657.
38. Yang R., Liu Y., Kelk P., et al. A subset of IL-17(+) mesenchymal stem cells possesses anti-Candida albicans effect. Cell Res. 2013, 23(1):107-121.
39. Nakamura K., Kitani A., Strober W. Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J. Exp. Med. 2001, 194(5):629-644.
40. Rubtsov Y.P., Rasmussen J.P., Chi E.Y., et al. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity 2008, 28(4):546-558.
41. Beyth S., Borovsky Z., Mevorach D., et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood 2005, 105(5):2214-2219.
42. Gieseke F., Bohringer J., Bussolari R., et al. Human multipotent mesenchymal stromal cells use galectin-1 to inhibit immune effector cells. Blood 2010, 116(19):3770-3779.
43. Ghannam S., Pene J., Torcy-Moquet G., et al. Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. J. Immunol. 2010, 185(1):302-312.
44. English K., Ryan J.M., Tobin L., et al. Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells. Clin Exp. Immunol. 2009, 156(1):149-160.
45. Liu X.J., Zhang J.F., Sun B., et al. Reciprocal effect of mesenchymal stem cell on experimental autoimmune encephalomyelitis is mediated by transforming growth factor-beta and interleukin-6. Clin Exp. Immunol. 2009, 158(1):37-44.
46. Parry R.V., Chemnitz J.M., Frauwirth K.A., et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol. Cell. Biol. 2005, 25(21):9543-9553.
47. Zhou Q., Munger M.E., Highfill S.L., et al. Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia. Blood 2010, 116(14):2484-2493.
48. Keir M.E., Francisco L.M., Sharpe A.H. PD-1 and its ligands in T-cell immunity. Curr. Opin. Immunol. 2007, 19(3):309-314.
49. Kitazawa Y., Fujino M., Wang Q., et al. Involvement of the programmed death-1/programmed death-1 ligand pathway in CD4+CD25+ regulatory T-cell activity to suppress alloimmune responses. Transplantation 2007, 83(6):774-782.
50. Shen T., Zheng J., Liang H., et al. Characteristics and PD-1 expression of peripheral CD4+CD127loCD25hiFoxP3+ Treg cells in chronic HCV infected-patients. Virol. J. 2011, 8:279.
51. Elrefaei M., Baker C.A., Jones N.G., et al. Presence of suppressor HIV-specific CD8+ T cells is associated with increased PD-1 expression on effector CD8+ T cells. J. Immunol. 2008, 180(11):7757-7763.
52. Dong H., Zhu G., Tamada K., et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat. Med. 1999, 5(12):1365-1369.
53. Meng Q., Yang P., Li B., et al. CD4+PD-1+ T cells acting as regulatory cells during the induction of anterior chamber-associated immune deviation. Invest. Ophthalmol. Vis. Sci. 2006, 47(10):4444-4452.
54. Brown J.A., Dorfman D.M., Ma F.R., et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J. Immunol. 2003, 170(3):1257-1266.
55. Figueira E.A., de Rezende M.L., Torres S.A., et al. Inhibitory signals mediated by programmed death-1 are involved with T-cell function in chronic periodontitis. J. Periodontol. 2009, 80(11):1833-1844.
56. Wong M., La Cava A., Hahn B.H. Blockade of programmed death-1 in young (New Zealand Black x New Zealand White)F1 mice promotes the suppressive capacity of CD4+ regulatory T cells protecting from lupus-like disease. J. Immunol. 2013, 190(11):5402-5410.
57. Gebler A., Zabel O., Seliger B. The immunomodulatory capacity of mesenchymal stem cells. Trends Mol. Med. 2012, 18(2):128-134.
58. Singer N.G., Caplan A.I. Mesenchymal stem cells: mechanisms of inflammation. Annu. Rev. Pathol. 2011, 6:457-478.